Please login to the form below

Not currently logged in
Email:
Password:

Mylan agrees $1.6bn deal to buy Agila injectables unit

Generics firm becomes “top three player” in injectables

Mylan headquarters

Consolidation continues apace in the generics sector, with Mylan agreeing a $1.6bn deal to acquire Strides Arcolab of India's sterile injectables business unit.

The deal for Bangalore-based Agila Specialties boosts Mylan's position in a therapeutic category which has been plagued by shortages in the US and elsewhere, as a result of manufacturing problems and some companies withdrawing from the market.

Mylan's chief executive Heather Bresch said absorbing Agila Specialities will make the company a "top three player" in injectables and double the company's turnover in the category to around $1bn in the first year after the acquisition concludes. The deal is expected to close in the fourth quarter of 2013.

"Agila brings us one of the most diversified, highest-quality and state-of-the-art injectables manufacturing bases in the industry", boosting capacity 50-fold, said Bresch on a conference call yesterday to discuss the deal and Mylan's fourth-quarter results.

The deal follows other large-scale M&A deals in the generics sector in recent months, notably the $5.9bn Watson-Actavis merger, Sandoz ' $1.53bn acquisition of Fougera Pharma and Sun Pharma's $600m transaction to take a majority-stage in Taro Pharma.

For Mylan, the deal follows the acquisitions of Merck KGaA's generics business for $6.7bn in 2008, a $550m deal for Ireland's Bioniche in 2010 and the $33m takeover of an SMS Pharma manufacturing facility in India, as well as an insulin analogue/biosimilar collaboration signed with Biocon earlier this month.

The proposed takeover also boosts its geographic presence, particularly in emerging pharma markets such as Brazil which accounts for a quarter of Agila Specialties' turnover, provides another platform for Mylan's biosimilar aspirations.

The agreement comes as Mylan reported record financial results in 2012, with revenues up 14 per cent to $6.8bn on the back of 600 product launches around the world, and earnings per share 27 per cent higher at $2.59.

28th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics